Orion Corporation Reports Strong 2025 Results, Boosted by Nubeqa Milestone
Event summary
- Orion Corporation reported a 22.5% increase in net sales to EUR 1,889.5 million for 2025, with Q4 sales up 60.1% year-over-year.
- Operating profit surged 51.6% to EUR 631.6 million, driven by a EUR 180 million Nubeqa milestone payment.
- The company proposes a dividend of EUR 1.80 per share, payable in two instalments.
- Outlook for 2026 projects net sales of EUR 1,900–2,100 million and operating profit of EUR 550–750 million.
- R&D expenses increased 17.2% to EUR 210.4 million, with new clinical trials initiated for ODM-212 and levosimendan.
The big picture
Orion’s strong 2025 performance underscores the strategic importance of its Nubeqa franchise, which has become a key growth driver. The company’s expansion in biologics R&D and its relocation to Boston reflect a broader industry trend of consolidating in biotech hubs to enhance innovation and partnerships. However, Orion’s reliance on milestone payments and foreign exchange risks poses challenges in maintaining consistent profitability.
What we're watching
- Nubeqa Growth Trajectory
- Whether Orion can sustain Nubeqa’s rapid sales growth and meet its target of EUR 1 billion annual net sales by the end of the decade.
- R&D Execution
- The pace at which Orion advances its clinical pipeline, particularly ODM-212, and the potential expansion of its phase 2 program in 2026.
- Market Risks
- How geopolitical tensions and supply chain disruptions may impact Orion’s production and profitability in 2026.
Related topics